Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.54 |
| ▸ | RXRB | P28702 | 2/20 | 0.54 |
| ▸ | RXRG | P48443 | 1/20 | 0.54 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | ICMT | O60725 | 5/20 | 0.44 |
| ▸ | POLQ | O75417 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17899450 | 0.84 | RXRA (0.72) | RXRARXRBRXRGDAOPOLQ | |
| SCHEMBL14060046 | 0.84 | RXRA (0.55) | RXRARXRBRXRGDAOPOLQ | |
| SCHEMBL12226966 | 0.83 | DAO (0.49) | RXRARXRBRXRGDAOKDM4E | |
| SCHEMBL16401777 | 0.83 | IDO1 (0.54) | DAOICMTPOLQKDM4EALDH1A1 | |
| SCHEMBL14562998 | 0.83 | POLQ (0.56) | DAOICMTPOLQALDH1A1CES2 | |
| SCHEMBL31434924 | 0.83 | IDO1 (0.54) | DAOICMTPOLQKDM4EALDH1A1 | |
| SCHEMBL7472612 | 0.82 | CES2 (0.44) | RXRARXRBRXRGICMTPOLQ | |
| SCHEMBL31434971 | 0.81 | DAO (0.46) | DAOICMTALDH1A1 | |
| SCHEMBL21541013 | 0.81 | ANO1 (0.51) | ICMTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL9890740 | 0.81 | PTGDR2 (0.46) | ICMTPOLQPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360118-A1 | Bicyclic Compounds and their Uses | NOVARTIS PHARMA AG (CH) | 2024-10-31 | — | — | US | disclosed |
| US-20070161677-A1 | Bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2007-07-12 | — | — | US | disclosed |
| US-20070161677-A1 | Bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2007-07-12 | — | — | US | disclosed |
| US-5846990-A | Substituted biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB CO. (US) | 1998-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161677-A1 | Bisarylurea derivatives | BRAF, RAF1, NRAS | RXRA 1619/4885RXRB 1471/4885RXRG 1761/4885 |
| US-20240360118-A1 | Bicyclic Compounds and their Uses | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, F12 | RXRA 1596/4885RXRB 2116/4885RXRG 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.